414PDPhase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors. (23rd October 2018) - Cho, B C; Perets, R; Bar, J; Ahn, M-J; Kim, D-W; Yoh, K; Nagrial, A; Spigel, D R; Lee, D H; Gutierrez, M; Kotasek, D; Siddiqi, S; et al.